. Author manuscript; available in PMC: 2013 Jun 1.

Published in final edited form as: Inflamm Bowel Dis. 2011 Aug 8;18(6):1048–1056. doi: 10.1002/ibd.21822

TABLE 2.

Hazard Ratios (95% CI) for primary outcome of 1^st oral steroid prescription associated with statin exposure in patients with inflammatory bowel disease overall, and for ulcerative colitis and Crohn’s disease

Exposure	IBD^*	UC	CD
Exposure	HR (95% CI)	HR (95% CI)	HR (95% CI)
Statin use
Unadjusted	0.90 (0.78, 1.04)	0.81 (0.67, 0.99)	1.01 (0.82, 1.24)
Adjusted	0.82 (0.71, 0.94)	0.75 (0.62, 0.91)	0.91 (0.74, 1.12)

HRs were determined via Cox proportional hazard models, adjusting for the Charlson comorbidity index, pre-exposure use of anti-TNF, 5-ASA, 6-MP/azathioprine, or rectal steroids, the number of outpatient contacts and hospitalization prior to exposure.

IBD includes cases of Crohn’s disease, ulcerative colitis, and indeterminate IBD.

IBD: inflammatory bowel disease; UC: ulcerative colitis; CD: Crohn’s disease; HR: Hazard ratio